Home
Science Corp Taps Leading Neurobiologist to Launch First Human Trials of Biohybrid Brain-Computer Interface
Science Corporation, a brain-computer interface (BCI) startup co-founded by Neuralink’s Max Hodak, has appointed Dr. Murat Günel, chairman of neurosurgery at Yale School of Medicine, as a scientific advisor. Dr. Günel will lead the company’s first U.S. human clinical trial for its biologically hybrid BCI system, marking a strategic shift from purely electronic devices to integrated biological-electronic solutions.

Founded in 2021 with a $1.5 billion valuation, Science Corporation recently closed a $230 million Series C funding round. The company’s core innovation avoids the brain damage risks associated with traditional rigid metal probes. Led by Chief Scientific Officer Alan Mardinly, the team is developing a biologically hybrid sensor that incorporates lab-grown neurons. This device uses light pulses to stimulate neurons, aiming for natural integration with the patient’s neural circuits rather than relying solely on electrical intervention.
The initial human trial will evaluate a micro-sensor equipped with 520 recording electrodes. Unlike Neuralink’s invasive implants, this sensor will be placed on the cerebral cortex surface within the skull, utilizing miniaturization to minimize risk. Dr. Günel plans to conduct preliminary validation on patients undergoing craniotomy, with future applications targeting Parkinson’s disease, post-stroke rehabilitation, and brain tumor monitoring.
While the company’s PRIMA vision restoration device is scheduled for promotion in Europe this year, this advanced biologically hybrid system requires extensive preparation for human trials. Dr. Günel noted that although a 2027 trial start date may be ambitious, the system holds the potential to halt neurodegenerative diseases, offering a new paradigm for human enhancement and medical treatment.
Related article
MiniMax 2.5 Tops Global Usage With Over $150M Monthly Revenue; M3 Flagship Version Set for H1 Release
Chinese large language models are generating intense momentum across the global developer ecosystem, driven by their reputation for cost-efficiency and engineering excellence.As of March 3, 2026, data from OpenRouter, the world’s leading API aggregat
Meta's Muse outpaces ChatGPT in early mobile launch
New data suggests Meta’s latest AI app, Muse, could become the social giant’s next major success. According to recent estimates from Appfigures, Muse has been downloaded on mobile devices more times in its first twelve days than ChatGPT did in the tw
TechCrunch Disrupt 2026: Clay’s Kareem Amin on the rise of the GTM engineer
Two years ago, GTM engineers were virtually nonexistent in most organizations. Today, the role is emerging across the tech sector, with professionals leveraging AI and automation to construct revenue engines that previously demanded multiple hires, d
Related Special Topic Recommendations
Comments (0)
0/500
Science Corporation, a brain-computer interface (BCI) startup co-founded by Neuralink’s Max Hodak, has appointed Dr. Murat Günel, chairman of neurosurgery at Yale School of Medicine, as a scientific advisor. Dr. Günel will lead the company’s first U.S. human clinical trial for its biologically hybrid BCI system, marking a strategic shift from purely electronic devices to integrated biological-electronic solutions.

Founded in 2021 with a $1.5 billion valuation, Science Corporation recently closed a $230 million Series C funding round. The company’s core innovation avoids the brain damage risks associated with traditional rigid metal probes. Led by Chief Scientific Officer Alan Mardinly, the team is developing a biologically hybrid sensor that incorporates lab-grown neurons. This device uses light pulses to stimulate neurons, aiming for natural integration with the patient’s neural circuits rather than relying solely on electrical intervention.
The initial human trial will evaluate a micro-sensor equipped with 520 recording electrodes. Unlike Neuralink’s invasive implants, this sensor will be placed on the cerebral cortex surface within the skull, utilizing miniaturization to minimize risk. Dr. Günel plans to conduct preliminary validation on patients undergoing craniotomy, with future applications targeting Parkinson’s disease, post-stroke rehabilitation, and brain tumor monitoring.
While the company’s PRIMA vision restoration device is scheduled for promotion in Europe this year, this advanced biologically hybrid system requires extensive preparation for human trials. Dr. Günel noted that although a 2027 trial start date may be ambitious, the system holds the potential to halt neurodegenerative diseases, offering a new paradigm for human enhancement and medical treatment.
MiniMax 2.5 Tops Global Usage With Over $150M Monthly Revenue; M3 Flagship Version Set for H1 Release
Chinese large language models are generating intense momentum across the global developer ecosystem, driven by their reputation for cost-efficiency and engineering excellence.As of March 3, 2026, data from OpenRouter, the world’s leading API aggregat
Meta's Muse outpaces ChatGPT in early mobile launch
New data suggests Meta’s latest AI app, Muse, could become the social giant’s next major success. According to recent estimates from Appfigures, Muse has been downloaded on mobile devices more times in its first twelve days than ChatGPT did in the tw
TechCrunch Disrupt 2026: Clay’s Kareem Amin on the rise of the GTM engineer
Two years ago, GTM engineers were virtually nonexistent in most organizations. Today, the role is emerging across the tech sector, with professionals leveraging AI and automation to construct revenue engines that previously demanded multiple hires, d











